Biotech | March 14, 2026
MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
The protections extend through at least 2035, with the potential for further extensions
The protections extend through at least 2035, with the potential for further extensions
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The NeuroSakhi initiative aims to close these gaps by strengthening awareness, building patient support networks and improving engagement between healthcare professionals, patients and caregivers across Punjab
Launches advanced bone density systems in India & Dubai
Industry leaders highlighted the pharmaceutical sector’s role in advancing research, innovation, early screening, and multi-stakeholder collaboration
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
The approval comes after a systematic review of published literature
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Giredestrant shows promise despite missing primary goal
Subscribe To Our Newsletter & Stay Updated
